You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Article metrics

Article menu

Download PDFPDF

XML
Short Report
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

 

Online download statistics by month:

Online download statistics by month: January 2020 to July 2025

AbstractFullPdf
Jan 202012120
Feb 202087870
Mar 202070703
Apr 202017317318
May 202022822812
Jun 2020797922
Jul 2020636341
Aug 2020524837
Sep 2020676756
Oct 2020747480
Nov 2020807956
Dec 2020686852
Jan 202110810867
Feb 202110710764
Mar 2021136136105
Apr 2021909074
May 2021124124105
Jun 2021959556
Jul 202113313364
Aug 202111611670
Sep 202110710771
Oct 2021150151114
Nov 2021171172108
Dec 202117317680
Jan 2022194202113
Feb 202217017994
Mar 202219620385
Apr 202221923393
May 202220721671
Jun 202223524498
Jul 202222723682
Aug 2022242247102
Sep 202224625266
Oct 2022221231108
Nov 202224324699
Dec 202222022444
Jan 202333734569
Feb 202325726571
Mar 202329530179
Apr 202318218786
May 202325325777
Jun 202321522155
Jul 202332733168
Aug 202323724376
Sep 202322422967
Oct 202328529068
Nov 202334134364
Dec 202338238560
Jan 2024124124111
Feb 202432933277
Mar 202449050377
Apr 202435736492
May 202437838487
Jun 202426427065
Jul 202441241683
Aug 202429530447
Sep 202431431764
Oct 202441242070
Nov 202447848588
Dec 202444044366
Jan 202544045065
Feb 202541041897
Mar 202534535178
Apr 202548248881
May 202537137499
Jun 202525425950
Jul 2025220
Total15115153774647